Serum BAFF and APRIL levels in patients with PBC

Kiyoshi Migita; Bibigul Ilyassova; Elena F. Kovzel; Alexander Nersesov; Seigo Abiru; Yumi Maeda; Atsumasa Komori; Masahiro Ito; Koji Yano; Hiroshi Yatsuhashi; Shinji Shimoda; Hiromi Ishibashi; Minoru Nakamura

doi:10.1016/j.clim.2009.09.007

Serum BAFF and APRIL levels in patients with PBC

Kiyoshi Migita, Bibigul Ilyassova, Elena F. Kovzel, Alexander Nersesov, Seigo Abiru, Yumi Maeda, Atsumasa Komori, Masahiro Ito, Koji Yano, Hiroshi Yatsuhashi, Shinji Shimoda, Hiromi Ishibashi, Minoru Nakamura

Department of Clinical Immunology and Rheumatology / Infectious Disease

Research output: Contribution to journal › Article › peer-review

26 Citations (Scopus)

Abstract

B-cell-activating factor belonging to the TNF family (BAFF) and a proliferation-inducing ligand (APRIL) are known to be involved in the occurrence of autoimmune diseases. We assessed serum levels of these cytokines in PBC patients. Serum BAFF levels were significantly higher in PBC patients than in healthy controls (1253.9 ± 741.4 vs. 722.8 ± 199.2 pg/ml; p < 0.0001) and HCV-infected patients (1253.9 ± 741.4 vs. 871.0 ± 251.1 pg/ml; p = 0.015). Whereas changes in serum APRIL levels were not significant among these groups, there was a significant correlation between BAFF and AST (R = 0.278, p = 0.003) or total bilirubin (R = 0.363, p = 0.0006) in PBC patients. Furthermore, serum BAFF levels were elevated in PBC patients with advanced interface hepatitis. Our data indicate that serum levels of BAFF and APRIL are differentially regulated and serum BAFF levels are significantly elevated in PBC patients. These findings suggest that BAFF may serve as a modulator of the clinical and/or serological manifestation in PBC patients.

Original language	English
Pages (from-to)	217-225
Number of pages	9
Journal	Clinical Immunology
Volume	134
Issue number	2
DOIs	https://doi.org/10.1016/j.clim.2009.09.007
Publication status	Published - Feb 2010

All Science Journal Classification (ASJC) codes

Immunology and Allergy
Immunology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clim.2009.09.007

Cite this

@article{27871f15f193426d9b5c3bb3b584e949,

title = "Serum BAFF and APRIL levels in patients with PBC",

abstract = "B-cell-activating factor belonging to the TNF family (BAFF) and a proliferation-inducing ligand (APRIL) are known to be involved in the occurrence of autoimmune diseases. We assessed serum levels of these cytokines in PBC patients. Serum BAFF levels were significantly higher in PBC patients than in healthy controls (1253.9 ± 741.4 vs. 722.8 ± 199.2 pg/ml; p < 0.0001) and HCV-infected patients (1253.9 ± 741.4 vs. 871.0 ± 251.1 pg/ml; p = 0.015). Whereas changes in serum APRIL levels were not significant among these groups, there was a significant correlation between BAFF and AST (R = 0.278, p = 0.003) or total bilirubin (R = 0.363, p = 0.0006) in PBC patients. Furthermore, serum BAFF levels were elevated in PBC patients with advanced interface hepatitis. Our data indicate that serum levels of BAFF and APRIL are differentially regulated and serum BAFF levels are significantly elevated in PBC patients. These findings suggest that BAFF may serve as a modulator of the clinical and/or serological manifestation in PBC patients.",

author = "Kiyoshi Migita and Bibigul Ilyassova and Kovzel, {Elena F.} and Alexander Nersesov and Seigo Abiru and Yumi Maeda and Atsumasa Komori and Masahiro Ito and Koji Yano and Hiroshi Yatsuhashi and Shinji Shimoda and Hiromi Ishibashi and Minoru Nakamura",

year = "2010",

month = feb,

doi = "10.1016/j.clim.2009.09.007",

language = "English",

volume = "134",

pages = "217--225",

journal = "Clinical Immunology",

issn = "1521-6616",

publisher = "Academic Press Inc.",

number = "2",

}

TY - JOUR

T1 - Serum BAFF and APRIL levels in patients with PBC

AU - Migita, Kiyoshi

AU - Ilyassova, Bibigul

AU - Kovzel, Elena F.

AU - Nersesov, Alexander

AU - Abiru, Seigo

AU - Maeda, Yumi

AU - Komori, Atsumasa

AU - Ito, Masahiro

AU - Yano, Koji

AU - Yatsuhashi, Hiroshi

AU - Shimoda, Shinji

AU - Ishibashi, Hiromi

AU - Nakamura, Minoru

PY - 2010/2

Y1 - 2010/2

N2 - B-cell-activating factor belonging to the TNF family (BAFF) and a proliferation-inducing ligand (APRIL) are known to be involved in the occurrence of autoimmune diseases. We assessed serum levels of these cytokines in PBC patients. Serum BAFF levels were significantly higher in PBC patients than in healthy controls (1253.9 ± 741.4 vs. 722.8 ± 199.2 pg/ml; p < 0.0001) and HCV-infected patients (1253.9 ± 741.4 vs. 871.0 ± 251.1 pg/ml; p = 0.015). Whereas changes in serum APRIL levels were not significant among these groups, there was a significant correlation between BAFF and AST (R = 0.278, p = 0.003) or total bilirubin (R = 0.363, p = 0.0006) in PBC patients. Furthermore, serum BAFF levels were elevated in PBC patients with advanced interface hepatitis. Our data indicate that serum levels of BAFF and APRIL are differentially regulated and serum BAFF levels are significantly elevated in PBC patients. These findings suggest that BAFF may serve as a modulator of the clinical and/or serological manifestation in PBC patients.

AB - B-cell-activating factor belonging to the TNF family (BAFF) and a proliferation-inducing ligand (APRIL) are known to be involved in the occurrence of autoimmune diseases. We assessed serum levels of these cytokines in PBC patients. Serum BAFF levels were significantly higher in PBC patients than in healthy controls (1253.9 ± 741.4 vs. 722.8 ± 199.2 pg/ml; p < 0.0001) and HCV-infected patients (1253.9 ± 741.4 vs. 871.0 ± 251.1 pg/ml; p = 0.015). Whereas changes in serum APRIL levels were not significant among these groups, there was a significant correlation between BAFF and AST (R = 0.278, p = 0.003) or total bilirubin (R = 0.363, p = 0.0006) in PBC patients. Furthermore, serum BAFF levels were elevated in PBC patients with advanced interface hepatitis. Our data indicate that serum levels of BAFF and APRIL are differentially regulated and serum BAFF levels are significantly elevated in PBC patients. These findings suggest that BAFF may serve as a modulator of the clinical and/or serological manifestation in PBC patients.

UR - http://www.scopus.com/inward/record.url?scp=73549094669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73549094669&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2009.09.007

DO - 10.1016/j.clim.2009.09.007

M3 - Article

C2 - 19840904

AN - SCOPUS:73549094669

SN - 1521-6616

VL - 134

SP - 217

EP - 225

JO - Clinical Immunology

JF - Clinical Immunology

IS - 2

ER -

Serum BAFF and APRIL levels in patients with PBC

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this